Here's a Multibillion-Dollar Market for Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) gained approval from the Food and Drug Administration for its multiple sclerosis drug, Ponvory, last month.
In this video from Motley Fool Live, recorded on March 22, Fool.com contributors Brian Orelli and Keith Speights discuss the prospects for Ponvory, which may be narrow because of its late entry into the space. But while the drug's prospects may be limited, they note that revenue from Ponvory is largely a bonus, on top of the pulmonary arterial hypertension drugs that Johnson & Johnson received through its acquisition of Actelion.
Source Fool.com
